An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial
M Natsuaki, H Watanabe, T Morimoto, K Yamamoto… - Circulation, 2024 - Am Heart Assoc
BACKGROUND: Bleeding rates on dual antiplatelet therapy (DAPT) within 1 month after
percutaneous coronary intervention (PCI) remain high in clinical practice, particularly in …
percutaneous coronary intervention (PCI) remain high in clinical practice, particularly in …
Dual antiplatelet therapy after percutaneous coronary intervention and drug-eluting stents: a systematic review and network meta-analysis
Background: The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous
coronary intervention with drug-eluting stents remains uncertain. We compared short-term (< …
coronary intervention with drug-eluting stents remains uncertain. We compared short-term (< …
Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: rationale and design of the TWILIGHT study
Background Dual antiplatelet therapy (DAPT) is necessary to prevent thrombosis yet
increases bleeding after percutaneous coronary intervention (PCI) with drug-eluting stents …
increases bleeding after percutaneous coronary intervention (PCI) with drug-eluting stents …
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an …
DA Gorog, JL Ferreiro, I Ahrens, J Ako… - Nature Reviews …, 2023 - nature.com
Conventional dual antiplatelet therapy (DAPT) for patients with acute coronary syndromes
undergoing percutaneous coronary intervention comprises aspirin with a potent P2Y …
undergoing percutaneous coronary intervention comprises aspirin with a potent P2Y …
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials
F Costa, C Montalto, M Branca, SJ Hong… - European Heart …, 2023 - academic.oup.com
Aims The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …
Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving …
H Watanabe, T Domei, T Morimoto, M Natsuaki… - Jama, 2019 - jamanetwork.com
Importance Very short mandatory dual antiplatelet therapy (DAPT) after percutaneous
coronary intervention (PCI) with a drug-eluting stent may be an attractive option. Objective …
coronary intervention (PCI) with a drug-eluting stent may be an attractive option. Objective …
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT …
Background Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y 12 inhibitor prevents
ischaemic events after coronary stenting, but increases bleeding. Guidelines support …
ischaemic events after coronary stenting, but increases bleeding. Guidelines support …
Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials
EP Navarese, F Andreotti, V Schulze, M Kołodziejczak… - bmj, 2015 - bmj.com
Objective To assess the benefits and risks of short term (< 12 months) or extended (> 12
months) dual antiplatelet therapy (DAPT) versus standard 12 month therapy, following …
months) dual antiplatelet therapy (DAPT) versus standard 12 month therapy, following …
Dual antiplatelet therapy for secondary prevention of coronary artery disease
S Degrauwe, T Pilgrim, A Aminian, S Noble… - Open …, 2017 - openheart.bmj.com
Dual antiplatelet therapy (DAPT) combining aspirin and a P2Y12 receptor inhibitor has been
consistently shown to reduce recurrent major adverse cardiovascular events (MACE) in …
consistently shown to reduce recurrent major adverse cardiovascular events (MACE) in …
Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials
Aims The aim of this study was to evaluate benefits and risks of extending dual antiplatelet
therapy (DAPT) after percutaneous coronary intervention (PCI) in the drug-eluting stent era …
therapy (DAPT) after percutaneous coronary intervention (PCI) in the drug-eluting stent era …